Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching

Welcome to STN International

NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus

NEWS 6 May 27 CAplus super roles and document types searchable in REGISTRY

NEWS 7 Jun 22 STN Patent Forums to be held July 19-22, 2004

NEWS 8 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT

NEWS 9 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)

NEWS 10 Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:24:41 ON 19 JUL 2004

=> file medline, uspatful, dgene, embase, wpids, biosis
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 15:25:37 ON 19 JUL 2004

FILE 'USPATFULL' ENTERED AT 15:25:37 ON 19 JUL 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:25:37 ON 19 JUL 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:25:37 ON 19 JUL 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:25:37 ON 19 JUL 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 15:25:37 ON 19 JUL 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s isolated protein
5 FILES SEARCHED...

L1 17016 ISOLATED PROTEIN

=> s secreted protein

3 FILES SEARCHED...

L2 407105 SECRETED PROTEIN

=> s 11 and 12

L3 3839 L1 AND L2

=> s 13 and heterologous protien

L4 0 L3 AND HETEROLOGOUS PROTIEN

=> s 13 and heterologous peptide

L5 7 L3 AND HETEROLOGOUS PEPTIDE

=> d 15 ti abs ibib tot

L5 ANSWER 1 OF 7 USPATFULL on STN

TI Leptin-related peptides

AB The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 200

2004:57925 USPATFULL Leptin-related peptides

INVENTOR(S):

TITLE:

Grasso, Patricia, Albany, NY, UNITED STATES Lee, Daniel W., Schenectady, NY, UNITED STATES

Leinung, Matthew C., Albany, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION:

US 2004043932 A1 20040304

APPLICATION INFO.:

US 2003-458334 A1 20030609 (10)

RELATED APPLN. INFO.:

Division of Ser. No. US 1999-377081, filed on 19 Aug

1999, PENDING

NUMBER DATE

PRIORITY INFORMATION:

US 1998-97457P

19980821 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,

ONE FINANCIAL CENTER, BOSTON, MA, 02111

NUMBER OF CLAIMS:

42

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

24 Drawing Page(s)

LINE COUNT:

3284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 7 USPATFULL on STN

TI Methods and materials relating to CD39-like polypeptides

The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a novel human CD39-like protein. Other aspects of the invention include vectors containing

polynucleotides of the invention and related host cells as well a processes for producing novel CD39-like polypeptides, and antibodies specific for such polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250966 USPATFULL

TITLE: Methods and materials relating to CD39-like

polypeptides

INVENTOR(S): Ford, John, San Mateo, CA, UNITED STATES

Mulero, Julio J., Palo Alto, CA, UNITED STATES Yeung, George, Mountain View, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:

US 2003175752 A1 20030918 US 2002-286926 A1 20021101 (10)

Continuation of Ser. No. US 2000-557800, filed on 25

Apr 2000, GRANTED, Pat. No. US 6476211

Continuation-in-part of Ser. No. US 2000-481238, filed on 11 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-370265, filed on 9 Aug 1999, GRANTED, Pat. No. US 6447771 Continuation-in-part of Ser. No. WO

1999-US16180, filed on 16 Jul 1999, PENDING

Continuation-in-part of Ser. No. US 1999-350836, filed

on 9 Jul 1999, GRANTED, Pat. No. US 6387645

Continuation-in-part of Ser. No. US 1999-273447, filed on 19 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-122449, filed on 24 Jul 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-244444, filed on 4 Feb 1999, ABANDONED Continuation of Ser. No. US

1998-118205, filed on 16 Jul 1998, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue,

Sunnyvale, CA, 94085

NUMBER OF CLAIMS: 46 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Page(s)

LINE COUNT: 5637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 7 USPATFULL on STN

TI Libraries of expressible gene sequences
AB The invention described herein comprises

The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:194491 USPATFULL

TITLE: Libraries of expressible gene sequences

INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED

STATES

Hoeffler, James Paul, Carlsbad, CA, UNITED STATES

PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

KIND DATE NUMBER -----US 2003134302 A1 20030717 US 2002-210985 A1 20020801 PATENT INFORMATION: APPLICATION INFO.:

Continuation of Ser. No. US 2001-3021, filed on 14 Nov RELATED APPLN. INFO.: 2001, PENDING Continuation of Ser. No. US 1999-285386,

filed on 2 Apr 1999, ABANDONED

NUMBER DATE \_\_\_\_\_

US 1998-96981P 19980818 (60) US 1998-80626P 19980403 (60) PRIORITY INFORMATION:

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE &

FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San

Diego, CA, 92121-2133

NUMBER OF CLAIMS: 40 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 9810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 7 USPATFULL on STN

ΤI Libraries of expressible gene sequences

AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106252 USPATFULL

TITLE: Libraries of expressible gene sequences

Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES INVENTOR (S): Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED

Hoeffler, James Paul, Carlsbad, CA, UNITED STATES

INVITROGEN CORPORATION (U.S. corporation) PATENT ASSIGNEE(S):

NUMBER KIND DATE -----US 2003073163 A1 20030417 US 2001-3021 A1 20011114 (10) PATENT INFORMATION:

APPLICATION INFO.:

Continuation of Ser. No. US 1999-285386, filed on 2 Apr RELATED APPLN. INFO.:

1999, PENDING

NUMBER DATE -----

US 1998-96981P 19980818 (60) PRIORITY INFORMATION:

US 1998-80626P 19980403 (60) DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE &

FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San

Diego, CA, 92121-2133

NUMBER OF CLAIMS: 40 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 9813

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 5 OF 7 USPATFULL on STN

Methods for regulation of immune responses to conditions involving ΤI

mediator-induced pathology

AB The present invention relates to methods for inhibiting the release and/or biological activity of the cytokine macrophage migration inhibitory factor (MIF). In particular, the invention relates to the uses of such methods for the treatment of various conditions involving mediator-induced diseases or pathology, which include, but are not limited to sepsis, severe sepsis, septic shock, inflammation, graft versus host disease, and/or autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:336863 USPATFULL

TITLE:

Methods for regulation of immune responses to

conditions involving mediator-induced pathology

INVENTOR(S): Calandra, Thierry, Lausanne, SWITZERLAND

Roger, Thierry, Lausanne, SWITZERLAND Glauser, Michel P., Lausanne, SWITZERLAND

NUMBER KIND DATE ------US 2002192217 A1 20021219 US 2002-94732 A1 20020307 PATENT INFORMATION: APPLICATION INFO.: A1 20020307 (10)

> NUMBER DATE

PRIORITY INFORMATION: US 2001-274004P 20010307 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C.,

One Financial Center, Boston, MA, 02111

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 2979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.5 ANSWER 6 OF 7 USPATFULL on STN

ΤI Methods and materials relating to CD39-like polypeptides

AΒ The invention provides polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a human CD39-like protein. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing CD39-like polypeptides, and antibodies specific for such polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:291077 USPATFULL

TITLE: Methods and materials relating to CD39-like

polypeptides

INVENTOR(S): Ford, John, San Mateo, CA, United States

Mulero, Julio J., Palo Alto, CA, United States Yeung, George, Mountain View, CA, United States

PATENT ASSIGNEE(S): Hyseq, Inc., Sunnyvale, CA, United States (U.S.

corporation)

NUMBER KIND DATE -----US 6476211 B1 20021105 PATENT INFORMATION:

APPLICATION INFO.: US 2000-557800 20000425 (9)

Continuation-in-part of Ser. No. US 2000-481238, filed RELATED APPLN. INFO.:

on 11 Jan 2000, now abandoned Continuation-in-part of

Ser. No. US 1999-370265, filed on 9 Aug 1999

Continuation-in-part of Ser. No. WO 1999-US16180, filed on 16 Jul 1999 Continuation-in-part of Ser. No. US 1999-350836, filed on 9 Jul 1999 Continuation-in-part

of Ser. No. US 1999-273447, filed on 19 Mar 1999, now abandoned Continuation-in-part of Ser. No. US 1998-122449, filed on 24 Jul 1998, now abandoned

Continuation-in-part of Ser. No. US 557800

Continuation-in-part of Ser. No. US 1999-244444, filed on 4 Feb 1999, now abandoned Continuation of Ser. No. US 1998-118205, filed on 16 Jul 1998, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Saunders, David ASSISTANT EXAMINER: DeCloux, Amy

Marshall, Gerstein & Borun LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS: 11 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 5844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 USPATFULL on STN

ΤI Methods and materials relating to CD39-like polypeptides

AΒ The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a novel human CD39-like protein. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing novel CD39-like polypeptides, and antibodies specific for such polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:926 USPATFULL

Methods and materials relating to CD39-like TITLE:

polypeptides

INVENTOR (S): Ford, John, San Mateo, CA, United States

Mulero, Julio J., Palo Alto, CA, United States Yeung, George, Mountain View, CA, United States

PATENT ASSIGNEE(S): Hyseq, Inc., Sunnyvale, CA, United States (U.S.

corporation)

NUMBER KIND DATE -----US 6335013 B1 20020101 PATENT INFORMATION:

APPLICATION INFO.: US 2000-608285 (9) 20000630 RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 2000-583231, filed on 26 May 2000 Continuation-in-part of Ser. No. US 2000-557800, filed on 25 Apr 2000 Continuation-in-part

of Ser. No. US 2000-481238, filed on 11 Jan 2000 Continuation-in-part of Ser. No. US 1999-370265, filed

on 9 Aug 1999 Continuation-in-part of Ser. No. WO

1999-US16180, filed on 16 Jul 1999 Continuation-in-part of Ser. No. US 1999-350836, filed on 9 Jul 1999

Continuation-in-part of Ser. No. US 1999-273447, filed

on 19 Mar 1999

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Saunders, David ASSISTANT EXAMINER: DeCloux, Amy

Marshall, Gerstein & Borun LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 4738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

		,	
	ruben, s		DUDEN ZANGUERTA TOCE/AU
E1 E2		1 2	RUBEN ZANCHETTA JOSE/AU RUBEN ZORRO/AU
E3			RUBEN, S/AU
E4		8	RUBENACH B/AU
E5		8	RUBENACH BERNHARD/AU
E6		2	RUBENACH GERZ K/AU
E7		1	RUBENACH I/AU
E8		1	RUBENACH J/AU
E9	1	.2	RUBENACH S/AU
E10		1	RUBENACH S E/AU
E11		4	RUBENACH SALLY/AU
E12		1	RUBENACH SALLY E/AU
=> e	rosen, c	:/au	
E1	-	2	ROSEN ZVI MICHAL/AU
E2		1	ROSEN ZWEIG JAMES/AU
E3		0>	ROSEN, C/AU
E4		1	ROSENA BRUCE R/AU
E5		1	ROSENABUM S/AU
E6		1	ROSENACKER A F/AU
E7		1	ROSENACKER ARTHUR F/AU
E8 E9		4	ROSENADA CEPERO R/AU ROSENAGER L/AU
E10		1	ROSENAK B/AU
E11	5	8	ROSENAK B/AU
E12		4	ROSENAK D/AU
			ROBERTINE B/ 110
=> e	zeng, z/	au	
E1	zeng, z/	1	ZENG ZULONG/AU
E1 E2	zeng, z/	1 3	ZENG ZUOTAO/AU
E1 E2 E3	zeng, z/	1 3 0>	ZENG ZUOTAO/AU ZENG, Z/AU
E1 E2 E3 E4	zeng, z/	1 3 0>	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU
E1 E2 E3 E4 E5	zeng, z/	1 3 0> 6 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU
E1 E2 E3 E4 E5 E6	zeng, z/	1 3 0> 6 3 2	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU
E1 E2 E3 E4 E5 E6	zeng, z/	1 3 0> 6 3 2 6	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU
E1 E2 E3 E4 E5 E6 E7 E8	zeng, z/	1 3 0> 6 3 2 6 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU
E1 E2 E3 E4 E5 E6	zeng, z/	1 3 0> 6 3 2 6 3 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9	zeng, z/	1 3 0> 6 3 2 6 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10	zeng, z/	1 3 0> 6 3 2 6 3 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12		1 3 0> 6 3 2 6 3 1 1 2 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12	zeng, z/	1 3 0> 6 3 2 6 3 1 1 2 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12		1 3 0> 6 3 2 6 3 1 1 2 1 /au 4	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU  MOORE ZACK J/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 => e		1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU  MOORE ZACK J/AU MOORE ZAKHIA/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12		1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU  MOORE ZACK J/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 => e E1 E2 E3		1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0>	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU  MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 => e E1 E2 E3 E4 E5 E6	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA FAU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINEN JOSEF/AU  MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU MOOREADIAN ARSHAG D/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 => e E1 E2 E3 E4 E5 E6 E7	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1 3	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA FRANCESCO/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINE J/AU MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU MOOREADIAN ARSHAG D/AU MOOREAU J/AU MOORECRAFT P/AU MOORECROFT B J/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 e E1 E2 E3 E4 E5 E6 E7 E7 E1 E1 E1 E1 E1 E1 E2 E3 E4 E5 E6 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1 3 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA FRANCESCO/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINE J/AU MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU MOOREADIAN ARSHAG D/AU MOOREAU J/AU MOORECRAFT P/AU MOORECROFT B J/AU MOORECROFT JAMES/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 E8 E9 E6 E7 E8 E7 E8 E9 E10 E11 E12 E12 E3 E4 E5 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1 3 1 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINE J/AU MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU MOOREADIAN ARSHAG D/AU MOOREAU J/AU MOORECRAFT P/AU MOORECROFT B J/AU MOORECROFT JAMES/AU MOORED J A/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 => e E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 E3 E4 E7 E10 E11 E12 E12 E3 E4 E4 E5 E6 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1 1 1 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFINE J/AU ZENGAFFINE J/AU MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE ZAKHIA/AU MOOREADIAN ARSHAG D/AU MOOREAU J/AU MOORECRAFT P/AU MOORECROFT B J/AU MOORED J A/AU MOORED J A/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 E8 E9 E6 E7 E8 E7 E8 E9 E10 E11 E12 E12 E3 E4 E5 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7	moore, p	1 3 0> 6 3 2 6 3 1 1 2 1 /au 4 3 0> 1 1 1 3 1 1	ZENG ZUOTAO/AU ZENG, Z/AU ZENGA A/AU ZENGA A I/AU ZENGA A I/AU ZENGA ANTONIO/AU ZENGA F/AU ZENGA FRANCESCO/AU ZENGA G B/AU ZENGA W/AU ZENGAFFINE J/AU ZENGAFFINE J/AU MOORE ZACK J/AU MOORE ZAKHIA/AU MOORE, P/AU MOOREADIAN ARSHAG D/AU MOOREAU J/AU MOORECRAFT P/AU MOORECROFT B J/AU MOORECROFT JAMES/AU MOORED J A/AU